NEW YORK (GenomeWeb) – Seahorse Bioscience and the Moffitt Cancer Center today said they have received a Small Business Innovation Research contract through the National Cancer Institute to develop a technology for measuring the metabolism of 3D tissue.

The technology, they said, would be developed for use in high-throughput metabolic and pre-clinical toxicity screens. According to a spokesperson for Seahorse Bio, the contract runs from September 2014 to June 2015 and is for $224,837.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.